Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Immunome reported positive Phase 3 RINGSIDE results for varegacestat in desmoid tumors, showing significant improvement in progression-free survival, a 56% response rate, and major tumor volume reduction versus placebo. The oral therapy was generally well tolerated, and Immunome plans an FDA filing in Q2 2026.